TRxADE Health, Inc. (NASDAQ: MEDS) is engaged as a health services IT company, which is focused on digitalizing the entire retail pharmacy process through drug procurement, prescription filling and patient notifications. Shares of the digital pharmacy service provider rallied 33.33% during trading on Tuesday, September 20, 2022. Over the past three months, TRxADE Health has seen average daily volume of 57,730 shares. However, volume of 29.12 million shares or dollar volume of around $39.6 million, exchanged hands during Tuesday’s trading session.
Shares of TRxADE Health gained after the company announced that its digital healthcare business subsidiary, Bonum Health, has entered into a telehealth services distribution agreement with Wakefern Food Corp. Under the deal, Bonum will launch telehealth services throughout Wakefern’s ShopRite pharmacy locations in New Jersey, New York, Pennsylvania, Maryland, and Connecticut.
Through Bonum Health’s Mobile Health Services application and prescriber program, the subsidiary will provide affordable telehealth services and prescription discounts to ShopRite pharmacy customers. The service allows patients to connect with board-certified medical providers to obtain the care and access to prescriptions needed. The Bonum Health app is available on both the Apple App and Google Play stores.
Dr. Shafaat Pirani, PharmD, BCGP, Chief Clinical and Compliance Officer for TRxADE notes: “We are ecstatic about working strategically with Wakefern Food Corp., the retailer-owned supermarket cooperative, to offer deep discounts for telemedicine services in the tristate area and neighboring states. The relationship speaks to the ethos of what Bonum Health is all about – improving access to healthcare services for the growing uninsured and under-insured population. Today, it is more important than ever to make sure people have affordable and accessible healthcare.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
